

Title of the Presentation:

Leading the Radioisotopes Cancer treatment revolution - What makes Alpha Tau's novel cancer treatment most promising in this new booming market?

By Ronen Segal, CTO, Alpha Tau Medical

- **Executive Summary / Investment Rational**

Alpha DaRT technology disrupts the Oncology field with a novel solid tumor treatment based on **Alpha particles**. After successfully and safely treating dozens of patients with deadly solid tumors, including those with unmet need like **Pancreatic** and **Brain** cancers, Alpha Tau has is leading the new solutions for this multi-billion market. Moreover, there has been demonstrated synergy with **Immunotherapy** (IO), that may lead to using a combination therapy, in cases where IO doesn't work. With the potential to treat millions of cancer patients around the world, Alpha Tau has managed to take the technology from the bench to a very successful first-in-human trial in the treatment of Skin and Head & Neck cancers. The technology was granted an FDA breakthrough device designation path. Partnering with top cancer research centers including Hadassah, Sheba, MD Anderson, Gustav Roissy, Mayo clinic, McGill University and many more. Raised more than \$100M in an IPO in the NASDAQ (**DRTS**). A very strong management team who previously led medical companies to big successes like Brainsway and Novocure.

- **Core Technology**

What is the technology, its uniqueness, and its value proposition?

Alpha DaRT™ Technology is based on Alpha particles that are known to be very destructive to tumor cells. They cause direct, irreparable damage to the cell DNA and lead to cell death. Using small, extremely precise amounts of radioactive radium-224 affixed to metal sources that are inserted into the tumor itself. When radium-224 decays, it releases radioactive atoms with short lifespans that diffuse inside the tumor. These atoms emit short-range alpha radiation that damages and kills cancer cells within a short period of time. This technology has the potential for treating millions of patients with no good standard treatment with minimal side effects.

- **Product Profile/Pipeline**

Most current indication on our pipeline are Pancreatic and Brain cancers. Following the first indication in humans for recurrent Skin and Head & Neck patients with more than 80% complete response. Next, we have clinical studies in **Lung, Prostate, Liver mets., and GYN cancers**.

- **Business Strategy**

Execute clinical validation for each product/indication treatment. Get reimbursement, and sell treatment kits. No capital investment is needed. Direct sales in the US. Current distribution agreement in other geographies.

- **What's Next?**

New study sites in different indications and territories. Build additional radioactive production facilities. Making the Alpha DaRT a standard treatment for cancer.